Drug Trial Radar · NCT07066436
ImmunoMRI for Assessment of Tumor-associated Macrophages
Last checked: Nov 20, 2026Latest source record: Jul 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Oct 2025
Primary completion
Mar 2028
Study completion Sep 2028
Sponsor
- Lead sponsor
- Medical University of ViennaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 15, 2025
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
About 35% of patients with a type of blood cancer called diffuse large B-cell lymphoma don't respond well to standard treatment or their cancer comes back. When this happens, newer treatments like CAR T-cell therapy (using modified immune cells) or bispecific antibodies (special proteins that help the immune system fight cancer) are an option. However, these treatments are only successful in about half the patients. It is currently difficult to predict which patients will respond to these treatments or experience serious side effects. This makes it hard to choose the best treatment plan for a given patient. In this project, a special type of magnetic resonance imaging (MRI) scan will be used to track immune cells called macrophages that live around tumors. These cells can either help fight cancer or help cancer grow. By understanding how these cells behave, it may be possible to predict treatment success. The MRI technique involves injecting an iron-based substance called ferumoxytol, which can be used as an MRI contrast agent, into patients' veins. This contrast agent gets absorbed by the macrophages, making them visible on MRI scans throughout the entire body - not just one tumor spot. Sixty patients will be scanned before and after treatment (30 getting CAR T-cells, 30 getting bispecific antibodies), and results will be compared with tissue samples. The goals are to predict which patients will go into complete remission, predict who will survive longer without cancer progression, and identify patients at risk for serious side effects like cytokine release syndrome. If successful, this imaging technique could help to personalize treatment choices, potentially improving outcomes while avoiding unnecessary toxicity in patients who will not benefit from these intensive therapies.
Conditions
- DLBCL - Diffuse Large B Cell Lymphoma
Interventions
MRI contrast-enhancing agentsDrug
1. Ferumoxytol will be injected as an off-label MRI contrast agent at a dose of 4 mg/kg body mass. For safety (in accordance with prior research), ferumoxytol will be diluted 1:4 in saline, and administered slowly over at least 15 minutes, with patient monitoring during and post injection. 2. ImmunoMRI will be performed using an iron sensitive fat-suppressed, fast spoiled gradient echo T2\* mapping sequence. At each time point (i.e. pre-treatment and post-treatment), T2\* mapping will be performed before and \~24h after ferumoxytol injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Correlation between immunoMRI and M1 and M2 TAM-directed IHCTime frame: Through study completion, 3 years
- Prediction of complete remission (CR)Time frame: Through study completion, 3 years
- Prediction of 1-year overall survival (OS)Time frame: Through study completion, 3 years
- Prediction of 1-year PFSTime frame: Through study completion, 3 years
- Prediction of development of treatment toxicities (CRS, ICANS)Time frame: Through study completion, 3 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Medical University of Vienna
Vienna, State of Vienna, Austria
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.